Biological, Genetic and Environmental Involved in the Complications of Sickle Cell Disease
NCT ID: NCT04205123
Last Updated: 2019-12-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
200 participants
OBSERVATIONAL
2014-10-20
2025-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The establishment of risk factors and indicators of severity will allow to target better the patients requiring an adequate strategy in order to prevent the installation of some complications or to limit their worsening.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A series ob biological but also genetic parameters, both at asymptomatic patients and those in aigüe phase of the disease, can be measured either immediately or a little time after the prelevement.
In this way, we can study numerous domains linked to the physiopathology of the drepanocytose (hémolyse, vaso-occlusion, rheology, factors modulators of the clinical expression). The surplus of the collection could be used for other researchs. It's in this context that we also wish to constitute a biobank of serum, plasma and urine for these drepanocytic patients by surplus of taken material.
The study is realized within the framework of an academic collaboration between institutions. The bank of takings will be located in the reference center of the pathologies of the Red Blood Cell (laboratory of medical chemistry of the erasme hospital).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
sickle cell syndrome
Inclusions of sickle cell patients aged over 17 years followed regularly in the participating centers.
sickle cell syndrome
Academic Study prospective multicenter observational factors responsible for nephropathy in patients with sickle cell disease followed by Belgium and the Nord-Pas -De- Calais Region and creating a biobank of blood and urine.
In the population of patients with SCD followed in all participating centres.
Know the prevalence of nephropathy and the relationship between it with their some of their genotypic mutations and clinical phenotype promoting mutated hemoglobin polymerization.
Determine the behaviour of dense cells in the basal state and in a hypeosmolaire environment
Determine the place of the erythrocyte microparticles as a biomarker of sickle cell nephropathy
Studying genes known as risk factor for proteinuria
Create a BioBank of samples of sickle cell patients in clinically stable condition for other research purposes.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
sickle cell syndrome
Academic Study prospective multicenter observational factors responsible for nephropathy in patients with sickle cell disease followed by Belgium and the Nord-Pas -De- Calais Region and creating a biobank of blood and urine.
In the population of patients with SCD followed in all participating centres.
Know the prevalence of nephropathy and the relationship between it with their some of their genotypic mutations and clinical phenotype promoting mutated hemoglobin polymerization.
Determine the behaviour of dense cells in the basal state and in a hypeosmolaire environment
Determine the place of the erythrocyte microparticles as a biomarker of sickle cell nephropathy
Studying genes known as risk factor for proteinuria
Create a BioBank of samples of sickle cell patients in clinically stable condition for other research purposes.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Signing an inform consent form after validation on it by the Ethics Committees of the participating centers.
Exclusion Criteria
* Severe CVO within the month preceding the sampling
* Transfusions within 3 months prior to sampling
* Pregnant patient or within 3 months post- accouhcement
17 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Erasme University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Erasme Hospital
Brussels, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
P2014/251
Identifier Type: -
Identifier Source: org_study_id